WKYMVm |
Catalog No.GC16498
One-Click Copy Product Info
|
WKYMVm, a synthetic peptide, is a potent Formyl peptide receptor 2 (FPR2) agonist, exerts an immunoregulatory effect.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 187986-17-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
WKYMVm, a synthetic peptide, is a potent Formyl peptide receptor 2 (FPR2) agonist, exerts an immunoregulatory effect[1]. WKYMVm activates FPR2 to stimulate phagocytes, thereby inducing the chemotaxis and calcium ion influx of phagocytes[2]. WKYMVm has been widely used to promote the homing of endothelial colony-forming cells to stimulate ischemic angiogenesis[3].
In vitro, WKYMVm treatment (10μM) for 1 minute induced the translocation of p47phox and NADPH-dependent superoxide production in serum-deprived human fibroblasts[4]. Treatment with 10μM WKYMVm for 72 hours inhibited the formation of mature osteoclasts induced by RANKL in RAW264.7 cells and reduced the intracellular ROS levels[5]. Treatment with 5μM WKYMVm for 2 hours decreased the lipopolysaccharide (LPS) induced-production of inflammatory cytokines in rat microglial cells, and suppressed the activities of the ERK1/2 and NF-κB p65 signaling pathways[6].
In vivo, WKYMVm administration via subcutaneous injection (8mg/kg) every 2 days for 5 weeks ameliorated high-fat diet (HFD)-induced obesity in mice, reduced food intake, and alleviated HFD-induced histological damage in the liver and adipose tissues[7]. Subcutaneously inject WKYMVm (8mg/kg) once every 12 hours for a total of 60 hours to improved ulcerative colitis in mice triggered by dextran sulphate sodium salt (DSS)[8].
References:
[1] Ma H, Guo X, Wang Z, et al. Therapeutic potential of WKYMVm in diseases[J]. Frontiers in Pharmacology, 2022, 13: 986963.
[2] Le Y, Gong W, Li B, et al. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation[J]. The Journal of Immunology, 1999, 163(12): 6777-6784.
[3] Heo S C, Kwon Y W, Jang I H, et al. WKYMVm-induced activation of formyl peptide receptor 2 stimulates ischemic neovasculogenesis by promoting homing of endothelial colony-forming cells[J]. Stem cells, 2014, 32(3): 779-790.
[4] Ammendola R, Russo L, De Felice C, et al. Low-affinity receptor-mediated induction of superoxide by N-formyl-methionyl-leucyl-phenylalanine and WKYMVm in IMR90 human fibroblasts[J]. Free Radical Biology and Medicine, 2004, 36(2): 189-200.
[5] Hu J, Li X, Chen Y, et al. The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF‐κB and CD9/gp130/STAT3 signalling pathway[J]. Journal of Cellular and Molecular Medicine, 2020, 24(2): 1893-1905.
[6] Zhang W, Chen J, Guo W, et al. WKYMVm/FPR2 alleviates spinal cord injury by attenuating the inflammatory response of microglia[J]. Mediators of inflammation, 2022, 2022(1): 4408099.
[7] Kang J H, Kim H S, Park S H, et al. WKYMVm ameliorates obesity by improving lipid metabolism and leptin signalling[J]. Journal of Cellular and Molecular Medicine, 2023, 27(18): 2782-2791.
[8] Kim S D, Kwon S, Lee S K, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis[J]. Experimental & molecular medicine, 2013, 45(9): e40-e40.
| Cell experiment [1]: | |
|
Cell lines |
Rat microglial cells |
|
Preparation Method |
Rat microglial cells were cultured in DMEM-F12 medium supplemented with 10% fetal bovine serum, 100units/ml penicillin, and 100mg/ml streptomycin at 37°C with 5% ambient CO2. Cells were seeded at a density of 1×103 cells/well in 6-well plates overnight. Cells were treated with or without different concentrations of WKYMVm (0, 1, 2, and 5μM) for 2 hours, and then LPS was added into the culture media at 1μg/ml for 24h. Inflammatory cytokine production in the cells was measured. |
|
Reaction Conditions |
0, 1, 2, and 5μM; 2h |
|
Applications |
WKYMVm treatment reduced the LPS-induced levels of TNF-α, IL-6, and IL-1β within rat microglial cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6N mice |
|
Preparation Method |
Male C57BL/6N mice (8-week-old) were housed on a 12h light/dark cycle and had free access to food and water at 22°C. Mice were fed with a HFD (60% fat as kcal) for 6 or 10 weeks. After 4 weeks of HFD feeding, obese mice received subcutaneous injections of vehicle (distilled water) or WKYMVm (8mg/kg) once every 2 days. During the 5 weeks of injection, the body weight (g) and food intake (g/week) of the mice were recorded every week. |
|
Dosage form |
8mg/kg; once every 2 days; 5 weeks; s.c. |
|
Applications |
WKYMVm treatment markedly decreased food intake and attenuated weight gain in obese mice. |
References: [1] Zhang W, Chen J, Guo W, et al. WKYMVm/FPR2 alleviates spinal cord injury by attenuating the inflammatory response of microglia[J]. Mediators of inflammation, 2022, 2022(1): 4408099. [2] Kang J H, Kim H S, Park S H, et al. WKYMVm ameliorates obesity by improving lipid metabolism and leptin signalling[J]. Journal of Cellular and Molecular Medicine, 2023, 27(18): 2782-2791. | |
| Cas No. | 187986-17-0 | SDF | |
| Chemical Name | (S)-6-amino-2-((S)-2-amino-3-(1H-indol-3-yl)propanamido)-N-((5R,8S,11S,14S)-5-carbamoyl-15-(4-hydroxyphenyl)-8-isopropyl-11-(2-(methylthio)ethyl)-7,10,13-trioxo-2-thia-6,9,12-triazapentadecan-14-yl)hexanamide | ||
| Canonical SMILES | O=C([C@H](CCCCN)NC([C@H](CC1=CNC2=CC=CC=C12)N)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](C(N)=O)CCSC)=O)C(C)C)=O)CCSC)=O)CC(C=C3)=CC=C3O | ||
| Formula | C41H61N9O7S2 | M.Wt | 856.11 |
| Solubility | Soluble to 2 mg/ml in Water | Storage | -20°C, protect from light |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1681 mL | 5.8404 mL | 11.6807 mL |
| 5 mM | 233.6 μL | 1.1681 mL | 2.3361 mL |
| 10 mM | 116.8 μL | 584 μL | 1.1681 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)